WO1995017154A3 - Use of thalidomide for treating neurocognitive disorders - Google Patents
Use of thalidomide for treating neurocognitive disorders Download PDFInfo
- Publication number
- WO1995017154A3 WO1995017154A3 PCT/US1994/014743 US9414743W WO9517154A3 WO 1995017154 A3 WO1995017154 A3 WO 1995017154A3 US 9414743 W US9414743 W US 9414743W WO 9517154 A3 WO9517154 A3 WO 9517154A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thalidomide
- treating
- neurocognitive disorders
- cholinergic deficit
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU13751/95A AU1375195A (en) | 1993-12-23 | 1994-12-22 | Use of thalidomide for treating neurocognitive disorders |
EP95904954A EP0735874A1 (en) | 1993-12-23 | 1994-12-22 | Use of thalidomide for treating neurocognitive disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/172,155 | 1993-12-23 | ||
US08/172,155 US5434170A (en) | 1993-12-23 | 1993-12-23 | Method for treating neurocognitive disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1995017154A2 WO1995017154A2 (en) | 1995-06-29 |
WO1995017154A3 true WO1995017154A3 (en) | 1995-07-13 |
Family
ID=22626590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/014743 WO1995017154A2 (en) | 1993-12-23 | 1994-12-22 | Use of thalidomide for treating neurocognitive disorders |
Country Status (4)
Country | Link |
---|---|
US (1) | US5434170A (en) |
EP (1) | EP0735874A1 (en) |
AU (1) | AU1375195A (en) |
WO (1) | WO1995017154A2 (en) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5739109A (en) * | 1988-12-16 | 1998-04-14 | Advanced Immunit Inc. | Method of treating neuroinflammatory degenerative diseases |
US8143283B1 (en) | 1993-03-01 | 2012-03-27 | The Children's Medical Center Corporation | Methods for treating blood-born tumors with thalidomide |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US5643915A (en) * | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5654312A (en) * | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
IT1276031B1 (en) * | 1995-10-31 | 1997-10-24 | Angelini Ricerche Spa | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
AU3224997A (en) * | 1996-05-29 | 1998-01-05 | Prototek, Inc | Prodrugs of thalidomide and methods for using same as modulators of t-cell function |
US6255347B1 (en) | 1996-06-21 | 2001-07-03 | Advanced Research And Technology Institute | Methods and compositions comprising R-ibuprofen |
EP2298300A1 (en) * | 1996-11-05 | 2011-03-23 | The Children's Medical Center Corporation | Compositions for inhibition of anglogenesis comprising thalidomide and aspirin |
FR2756737B1 (en) * | 1996-12-05 | 1999-01-08 | Rhone Poulenc Rorer Sa | APPLICATION OF THALIDOMIDE TO THE TREATMENT OF PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES |
US6664239B2 (en) * | 1997-05-06 | 2003-12-16 | Vanderbilt University | Diagnosis and management of infection caused by Chlamydia |
WO1998052563A1 (en) * | 1997-05-21 | 1998-11-26 | Shionogi & Co., Ltd. | REMEDIES FOR DEMENTIA OF ALZHEIMER TYPE CONTAINING η-SULTAM DERIVATIVES |
DE19743968C2 (en) * | 1997-10-06 | 2002-07-11 | Gruenenthal Gmbh | Intravenous application form of thalidomide for the therapy of immunological diseases |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US7588766B1 (en) | 2000-05-26 | 2009-09-15 | Elan Pharma International Limited | Treatment of amyloidogenic disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6458777B1 (en) * | 1998-03-13 | 2002-10-01 | Mucosal Therapeutics Llc | Methods and compositions for treating and preventing mucositis |
US20050059802A1 (en) * | 1998-04-07 | 2005-03-17 | Neuralab Ltd | Prevention and treatment of amyloidogenic disease |
US6673828B1 (en) | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6262081B1 (en) * | 1998-07-10 | 2001-07-17 | Dupont Pharmaceuticals Company | Composition for and method of treating neurological disorders |
US6218383B1 (en) * | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
US6440967B1 (en) * | 1998-11-12 | 2002-08-27 | Merck & Co., Inc. | Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E |
US6423321B2 (en) | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) * | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
WO2001078721A1 (en) * | 2000-04-13 | 2001-10-25 | Mayo Foundation For Medical Education And Research | Aβ42 LOWERING AGENTS |
US20060004086A1 (en) * | 2000-04-13 | 2006-01-05 | Mayo Foundation For Medical Education And Research | Method of reducing Abeta42 and treating diseases |
US6781029B2 (en) | 2000-07-13 | 2004-08-24 | University Of South Florida | Transgenic animal and methods |
ES2290091T3 (en) * | 2000-11-30 | 2008-02-16 | The Children's Medical Center Corporation | SYNTHESIS OF ENANTIOMERS OF 4-AMINO-TALIDOMIDE. |
TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
ATE450529T1 (en) * | 2001-02-27 | 2009-12-15 | Governement Of The United Stat | ANALOGUE OF THALIDOMIDE AS ANGIOGENESIS INHIBITORS |
EP1572894B1 (en) * | 2001-11-21 | 2016-04-13 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto |
US20030164219A1 (en) * | 2002-02-20 | 2003-09-04 | Joerg Brahm | Headliner/duct assembly and welding process therefor |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
GB0207529D0 (en) * | 2002-04-02 | 2002-05-08 | Norbrook Lab Ltd | Injectable veterinary composition for small animals |
US9006267B2 (en) * | 2002-11-14 | 2015-04-14 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
WO2004056318A2 (en) * | 2002-12-19 | 2004-07-08 | New York University | Method for treating amyloid disease |
PL378571A1 (en) * | 2003-02-01 | 2006-05-02 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | Method and composition for treating neurodegenerative disorders |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP1628532A2 (en) * | 2003-05-30 | 2006-03-01 | Microbia, Inc. | Methods for the protection of memory and cognition |
US20050042284A1 (en) * | 2003-07-11 | 2005-02-24 | Myriad Genetics, Incorporated | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease |
US7973057B2 (en) * | 2003-09-17 | 2011-07-05 | The United States Of America As Represented By The Department Of Health And Human Services | Thalidomide analogs |
US8952895B2 (en) | 2011-06-03 | 2015-02-10 | Apple Inc. | Motion-based device operations |
NZ547127A (en) * | 2003-10-24 | 2008-06-30 | Celgene Corp | Methods and compositions comprising thalidomide for treatment of fibromyalgia |
US20050182097A1 (en) * | 2003-12-30 | 2005-08-18 | Zeldis Jerome B. | Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
WO2005092062A2 (en) * | 2004-03-19 | 2005-10-06 | Myriad Genetics, Inc. | Compounds for neurodegenerative disorders |
US20050222127A1 (en) * | 2004-03-30 | 2005-10-06 | Alcon, Inc. | Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance |
WO2006001877A2 (en) * | 2004-04-13 | 2006-01-05 | Myriad Genetics, Inc. | Combination treatment for neurodegenerative disorders comprising r-flurbiprofen |
KR20070004036A (en) * | 2004-04-29 | 2007-01-05 | 키스톤 리테이닝 월 시스템스, 아이엔씨 | Veneers for walls, retaining walls and the like |
WO2006020850A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
WO2006020852A2 (en) * | 2004-08-11 | 2006-02-23 | Myriad Genetics, Inc. | Pharmaceutical composition and method for treating neurodegenerative disorders |
BRPI0514303A (en) * | 2004-08-11 | 2008-06-10 | Myriad Genetics Inc | pharmaceutical composition and method for treating neurodegenerative disorders |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
AR052051A1 (en) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | AB HUMANIZED ANTIBODIES USED TO IMPROVE COGNITION |
AR051528A1 (en) * | 2004-12-15 | 2007-01-17 | Neuralab Ltd | HUMANIZED ANTIBODIES RECOGNIZING THE BETA AMILOIDEO PEPTIDE |
EP1838349A1 (en) * | 2004-12-15 | 2007-10-03 | Neuralab, Ltd. | Amyloid beta antibodies for use in improving cognition |
EP1909777A2 (en) * | 2005-07-22 | 2008-04-16 | Myriad Genetics, Inc. | High drug load formulations and dosage forms |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
EP2046119A2 (en) * | 2006-07-07 | 2009-04-15 | Myriad Genetics, Inc. | Treatment of psychiatric disorders |
WO2008124585A1 (en) * | 2007-04-06 | 2008-10-16 | Board Of Governors For Higher Education, State Of Rhode Island And Providence Planations | Lowering of proteins associated with alzheimer's disease by interrupting gene transcription with a small molecule |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
PT2182983E (en) | 2007-07-27 | 2014-09-01 | Janssen Alzheimer Immunotherap | Treatment of amyloidogenic diseases with humanised anti-abeta antibodies |
JO3076B1 (en) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | Immunotherapy regimes dependent on apoe status |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
US20170044096A1 (en) | 2013-03-15 | 2017-02-16 | Rutgers, The State University Of New Jersey | Augmenting Moieties for Anti-Inflammatory Compounds |
WO2010051044A1 (en) * | 2008-11-03 | 2010-05-06 | University Of Medicine And Dentistry | Unique dual-action therapeutics |
US11731991B2 (en) | 2008-11-03 | 2023-08-22 | Lehigh University | Augmenting moieties for anti-inflammatory compounds |
JP5339588B2 (en) * | 2008-11-10 | 2013-11-13 | 国立大学法人 新潟大学 | A therapeutic drug for schizophrenia containing thalidomide or its derivatives as an active ingredient |
US8906382B2 (en) | 2011-07-19 | 2014-12-09 | New York University | Method for treating amyloid disease |
WO2013012811A2 (en) | 2011-07-19 | 2013-01-24 | New York University | Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
WO1995004533A2 (en) * | 1993-08-04 | 1995-02-16 | Andrulis Pharmaceuticals Corporation | Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2830991A (en) * | 1954-05-17 | 1958-04-15 | Gruenenthal Chemie | Products of the amino-piperidine-2-6-dione series |
DE3582995D1 (en) * | 1984-10-25 | 1991-07-04 | Hoechst Roussel Pharma | 9-AMINO-1,2,3,4-TETRAHYDROACRIDIN-1-OL AND RELATED COMPOUNDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS A MEDICINAL PRODUCT. |
US4816456A (en) * | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
US5210087A (en) * | 1991-02-13 | 1993-05-11 | Hoechst-Roussel Pharmaceuticals Inc. | 9-aminotetrahydroacridines and related compounds |
TW239127B (en) * | 1991-12-20 | 1995-01-21 | Hoffmann La Roche |
-
1993
- 1993-12-23 US US08/172,155 patent/US5434170A/en not_active Expired - Lifetime
-
1994
- 1994-12-22 WO PCT/US1994/014743 patent/WO1995017154A2/en not_active Application Discontinuation
- 1994-12-22 AU AU13751/95A patent/AU1375195A/en not_active Abandoned
- 1994-12-22 EP EP95904954A patent/EP0735874A1/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
WO1995004533A2 (en) * | 1993-08-04 | 1995-02-16 | Andrulis Pharmaceuticals Corporation | Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents |
Non-Patent Citations (3)
Title |
---|
H. FILLIT: "Elevated circulating tumor necrosis factor levels in Alzheimer's disease", NEUROSCI. LETTERS, vol. 129, no. 2, 1991, pages 318 - 320 * |
P.L. MCGEER: "Anti-inflammatory drugs and Alzheimer disease.", THE LANCET, vol. 335, no. 8696, 1990, pages 1037 * |
S.S. HENDLER: "Thalidomide for autoimmune disease", MED. HYPOTHESES, vol. 10, no. 4, 1983, pages 437 - 443 * |
Also Published As
Publication number | Publication date |
---|---|
AU1375195A (en) | 1995-07-10 |
WO1995017154A2 (en) | 1995-06-29 |
EP0735874A1 (en) | 1996-10-09 |
US5434170A (en) | 1995-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995017154A3 (en) | Use of thalidomide for treating neurocognitive disorders | |
US5037384B1 (en) | Method and apparatus for the treatment of complicated retinal detachments | |
EP0727985A4 (en) | Composition and method for treating blood vessel disorders of the skin using vitamin k | |
NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
DE69739792D1 (en) | Method for the treatment of eye diseases | |
EP1366770A3 (en) | Use of botulinum toxin for treating muscle-associated pain | |
AU6760987A (en) | Method of treating alzheimer's disease | |
ATE213411T1 (en) | USE OF PHENSERINE IN THE PRODUCTION OF MEDICATIONS FOR THE TREATMENT OF COGNITIVE DISORDERS | |
DE69731540D1 (en) | TREATMENT OF DIARRHOE | |
EP0651650A4 (en) | METHOD OF TREATING OPHTHALMIC DISORDERS USING TGF--g(b). | |
DK0723444T3 (en) | Levobupivacaine suitable for the treatment of chronic pain | |
WO1997003188A3 (en) | Use of mp52 or mp121 for treating and preventing diseases of the nervous system | |
HU891056D0 (en) | Process for treating the diseases of the gullet and the stomach-intestine system | |
EP0267297A4 (en) | Sialosylcholesterol, process for its preparation, and drug for treating diseases of nervous system. | |
NZ324615A (en) | Method for treating autism using olanzapine | |
PL335802A1 (en) | Method of treating vascular disorders | |
Sykes et al. | The use of group therapy in the treatment of bulimia. | |
DE68909750D1 (en) | DEVICE FOR THE THERAPEUTIC TREATMENT OF LUMBAGO AND LUMBAGO / ISCHIAS. | |
EP0745597A3 (en) | Novel melatonergic indanyl piperazines or homopiperazines | |
DE3585312D1 (en) | APPLICATION OF 1,6-DIMETHYL-4-OXO-1,6,7,8,9A-HEXAHYDRO-4H-PYRIDO (1,2-A) PYRIMIDIN-3-CARBOXAMIDE FOR THE PREVENTION AND TREATMENT OF GASTROINTESTINAL DAMAGE. | |
张育勤 | A REPORT OF 49 CASES OF DYSMENORRHEA TREATED BY ACUPUNCTURE | |
RU93057223A (en) | METHOD OF TREATMENT OF PARALISES AND PARESIS | |
CA2147749A1 (en) | Therapeutic agent for diseases of periodontal tissue | |
葛通远 et al. | AN APPROACH TO THE MECHANISMS OF LASER ACUPUNCTURE IN TREATMENT OF EXOPHTHALMIC HYPERTHYROIDISM | |
RU93037466A (en) | METHOD FOR TREATING PERIPHERAL NEUROPATHIES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA CN JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA CN JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995904954 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995904954 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995904954 Country of ref document: EP |